Bangkok Genomics Innovation Public Company Limited (BKGI.BK)

Stock analysis · SET · Healthcare · Medical - Diagnostics & Research

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

1.31

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Bangkok Genomics Innovation Public Company Limited (BKGI.BK) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 19, 2026

EPS $0.05 vs est. $0.02

Beat by $0.03

Proprietary Signals

Signal snapshot temporarily unavailable.

About Bangkok Genomics Innovation Public Company Limited

Bangkok Genomics Innovation Public Company Limited, trading as BKGI.BK, is a Thailand-based enterprise delivering a diverse array of clinical and genomic services. Their core genetic offerings include the NIFTY brand for non-invasive prenatal testing, screening for fetal chromosomal abnormalities, and the VISTA brand, which provides genetic disease carrier screening for applications such as pre-embryo implantation, general carrier status, and the detection of gene anomalies linked to thalassemia anemia. Additionally, they offer HPV DNA testing, colon cancer screening under the COLOTECH brand, and personalized genetic analyses through the DNALL brand. Beyond genetic diagnostics, the company provides comprehensive testing for infectious diseases, including real-time PCR, antigen, serology, and neutralizing antibody assays for COVID-19, alongside real-time PCR testing for the monkeypox virus. Their technology solutions segment covers advanced services like DNA and RNA base sequencing, as well as metabolism and protein omics tests. The company also acts as a distributor for essential medical supplies, such as PCR COVID-19 test kits, personal protective equipment (PPE), and vital trans…